Pillar 1 - FTO (new thread), page-965

1. Yesp, two or more.
2. Metformin approved for Type 2 Diabetes - Put simply, it 1) reduces blood glucose in the body (main function), while also 2) helping lose body fat (secondary downstream function), which decreases peripheral inflammation, lipotoxicity (high levels of fat in blood), and insulin resistance improving the treatment of type 2 diabetes. Considered the number one drug for Type 2 Diabetes.
3. It would be a single agent trial with multiple effects.
4. Lol.

If you think about it, Bisantrene should have more than one self-synergy. Example below - overexpression of A (from m6A) icreases cancer as well as obesity, which obesity itself is a risk factor for cancer. By inhibiting FTO, you can reduce cancer (evidence building) and you can decrease fat stores (preclinical studies support this), which by decreasing fat stores would have a flow on effect to reducing cancer.



Personally, I think Bisantrene is a pretty poor anthracene-like drug and have doubts about the synergy model - if there is an effect, I think it would be mild and largely due to the inhibition of FTO sensitizing cancer cells. Happy to provide discussion around that point, but I think reading my previous post here has covered it.

All IMO.